peramivir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals neuraminidase inhibitors | 4823 | 330600-85-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Peramivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| fu (Fraction unbound in plasma) | 1 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| CL (Clearance) | 1.46 mL/min/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 13, 2018 | EMA | BIOCRYST UK LIMITED | |
| Dec. 19, 2014 | FDA | BIOCRYST |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AH03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Neuraminidase inhibitors |
| FDA MoA | N0000175436 | Neuraminidase Inhibitors |
| FDA EPC | N0000175524 | Neuraminidase Inhibitor |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| CHEBI has role | CHEBI:36044 | antiviral drugs |
| CHEBI has role | CHEBI:52425 | acetylneuraminidase inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Influenza | indication | 6142004 | DOID:8469 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.6 | acidic |
| pKa2 | 12.05 | acidic |
| pKa3 | 13.73 | acidic |
| pKa4 | 10.07 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 10391075 | Feb. 12, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 10391075 | Feb. 12, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sialidase 2 | Enzyme | Ki | 4.25 | CHEMBL | |||||
| Neuraminidase | Enzyme | INHIBITOR | IC50 | 8.85 | CHEMBL | DRUG LABEL | |||
| Neuraminidase | Enzyme | INHIBITOR | IC50 | 8.30 | CHEMBL | DRUG LABEL | |||
| Neuraminidase | Enzyme | INHIBITOR | Ki | 9.08 | CHEMBL | DRUG LABEL | |||
| Neuraminidase | Enzyme | IC50 | 9.40 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 10.15 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 8.70 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 7.03 | CHEMBL | |||||
| Sialidase | Enzyme | IC50 | 4.40 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 9.52 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D03829 | KEGG_DRUG |
| 1041434-82-5 | SECONDARY_CAS_RN |
| 4034033 | VANDF |
| CHEBI:85196 | CHEBI |
| BCZ | PDB_CHEM_ID |
| CHEMBL3989402 | ChEMBL_ID |
| CHEMBL139367 | ChEMBL_ID |
| C414210 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB06614 | DRUGBANK_ID |
| 1598078 | RXNORM |
| 231961 | MMSL |
| 30814 | MMSL |
| d08335 | MMSL |
| 013296 | NDDF |
| 716121006 | SNOMEDCT_US |
| 763542005 | SNOMEDCT_US |
| C1675326 | UMLSCUI |
| 154234 | PUBCHEM_CID |
| QW7Y7ZR15U | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61364-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 27 sections |
| Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72769-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 31 sections |
| Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72769-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 31 sections |